cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-2181Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMКлиническая фармакология комбинации ингибиторов ангиотензин-превращающего фермента и антагонистов кальция: преимущества комбинации периндоприла аргинина и амлодипинаClinical pharmacology of the combination of ACE inhibitors and calcium antagonists: benefits of the perindopril arginine and amlodipine combinationЛеоноваМ. В.LeonovaM. V.

профессор кафедры клинической фармакологии

anti23@mail.ruГОУ ВПО Российский государственный медицинский университет Росздрава. МоскваRussian State Medical University. Moscow201001011970985562Copyright © Леонова М.В., 19701970Леонова М.В.Leonova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2181

Представлены современные данные по механизмам действия и клинической эффективности двух классов кардиоваскулярных препаратов – ингибиторов ангиотензин-превращающего фермента (ИАПФ) и антагонистов кальция (АК), в аспекте их применения у пациентов с артериальной гипертонией (АГ) и ишемической болезнью сердца (ИБС). ИАПФ и АК обладают комплементарным механизмом действия на тонус сосудов и дисфункцию эндотелия, обеспечивают синергизмом действия в снижении артериального давления (АД), а также в достижении плейотропных и органопротективных эффектов, уменьшении развития неблагоприятных исходов, что обосновывает предпосылки для их сочетанного применения в лечении кардиоваскулярных заболеваний. Наибольшее практическое значение и доказательную базу имеют периндоприл и амлодипин, применяющиеся как в монотерапии, так и в виде комбинации.

The paper reviews the modern evidence on mechanisms of action and clinical effectiveness of two cardiovascular medication classes – angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists (CA), used for the treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD). ACE inhibitors and CA have complementary effects on vascular tone and endothelial function, as well as synergetic action in terms of blood pressure (BP) reduction, pleiotropic effects, organo-protection, and clinical event prevention. Therefore, these mediations can be used as combined cardiovascular therapy. Perindopril and amlodipine, both as monotherapy or combined treatment, have the largest evidence base and potential for clinical practice.

ренин-ангиотензиновая системадисфункция эндотелияингибиторы ангиотензинпревращающего ферментаантагонисты кальцияартериальная гипертонияишемическая болезнь сердцаrenin-angiotensin systemendothelial dysfunctionACE inhibitorscalcium antagonistsarterial hypertensioncoronary heart diseaseReferencesШальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. РКЖ 2006; 4: 45-50.Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. РКЖ 2006; 4: 45-50.Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.Zhou M-S, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24: 366-78.Zhou M-S, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24: 366-78.Soubrier F, Alhenc-Gelas F, Hubert C, et al. Two putative active centers in human angiotensin Iconverting enzyme revealed by molecular cloning. Proc Natl Acad Sci 1988; 85: 9386-90.Soubrier F, Alhenc-Gelas F, Hubert C, et al. Two putative active centers in human angiotensin Iconverting enzyme revealed by molecular cloning. Proc Natl Acad Sci 1988; 85: 9386-90.Dive V, Cotton J, Yiotakis A, et al. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci 1999; 96: 4330-5.Dive V, Cotton J, Yiotakis A, et al. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci 1999; 96: 4330-5.Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1-6.Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1-6.Comini L, Bachetti T, Cargnoni A, et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharm Res 2007; 56: 42-8.Comini L, Bachetti T, Cargnoni A, et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharm Res 2007; 56: 42-8.Ceconi C, Francolini G, Bastianon D. Differences in the Effect of Angiotensin-converting enzyme iInhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007; 21: 423-9.Ceconi C, Francolini G, Bastianon D. Differences in the Effect of Angiotensin-converting enzyme iInhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007; 21: 423-9.Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237-46.Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237-46.Hernaґndez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Therap 2003; 10: 409-14.Hernaґndez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Therap 2003; 10: 409-14.Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34: 869-77.Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34: 869-77.Mason RP, Walter MF, Trumbore MW, et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31,: 275-81.Mason RP, Walter MF, Trumbore MW, et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31,: 275-81.Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-80.Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-80.Zhang X-P, Loke KE, Mital S, et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R-enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39: 208-14.Zhang X-P, Loke KE, Mital S, et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R-enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39: 208-14.Roth M, Eickelberg O, Köhler E, et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci 1996; 93: 5478-82.Roth M, Eickelberg O, Köhler E, et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci 1996; 93: 5478-82.Nayler WG. The antiatherogenic effects of amlodipine: Promise of preclinical data. J Hum Hypertens 1992; 6: S19-23.Nayler WG. The antiatherogenic effects of amlodipine: Promise of preclinical data. J Hum Hypertens 1992; 6: S19-23.Pitt B, Byington RP, Furberg CD, et al., for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Pitt B, Byington RP, Furberg CD, et al., for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Nissen SE, Tuzcu EM, Libby P, et al., for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Nissen SE, Tuzcu EM, Libby P, et al., for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Costanzo MP, Perrone-Filardi MP, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients. J Hypertens 2009; 27: 1136-51.Costanzo MP, Perrone-Filardi MP, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients. J Hypertens 2009; 27: 1136-51.Ferreri R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodopine. Curr Med Res Opin 2008; 24(12): 3543-57.Ferreri R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodopine. Curr Med Res Opin 2008; 24(12): 3543-57.Bahl VR, Jadhav UM, Thracker HP. Management of hypertension with fixed combination of perindopril and amlodipine in daily clinical practice. Am J Cardiovasc Drugs 2009; 9: 135-42.Bahl VR, Jadhav UM, Thracker HP. Management of hypertension with fixed combination of perindopril and amlodipine in daily clinical practice. Am J Cardiovasc Drugs 2009; 9: 135-42.Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Coundit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213-25.Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Coundit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213-25.Zhang X-P, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kininmediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol 2000; 35: 195-202.Zhang X-P, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kininmediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol 2000; 35: 195-202.Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-a production after cardiac ischemia. J Cardiovasc Pharmacol 2006; 47: 636-42.Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-a production after cardiac ischemia. J Cardiovasc Pharmacol 2006; 47: 636-42.Jugdutt BI, Menon V, Kumar D, Idikio H. Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. JACC 2002; 39: 1538-45.Jugdutt BI, Menon V, Kumar D, Idikio H. Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. JACC 2002; 39: 1538-45.Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006; 19: 129-39.Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006; 19: 129-39.Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890-9.Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890-9.Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 1042-9.Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 1042-9.Fogari R, Zoppi A, Mugellini A, et al. Effects of amlodipine, nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebocontrolled, double-masked, crossover study. Cur Therap Res 1999; 60(3): 121-8.Fogari R, Zoppi A, Mugellini A, et al. Effects of amlodipine, nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebocontrolled, double-masked, crossover study. Cur Therap Res 1999; 60(3): 121-8.Dahlof B, Sever PS, Poulter NR, et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Dahlof B, Sever PS, Poulter NR, et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Jamerson KA, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.Jamerson KA, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium-channel blocker in prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010; 159: 795-802.Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium-channel blocker in prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010; 159: 795-802.

The authors declare that there are no conflicts of interest present.